{"id":6737,"date":"2024-04-24T05:30:00","date_gmt":"2024-04-24T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/delarsrapport-januari-mars-2024\/"},"modified":"2024-04-24T05:30:00","modified_gmt":"2024-04-24T05:30:00","slug":"delarsrapport-januari-mars-2024","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/","title":{"rendered":"Del\u00e5rsrapport januari-mars 2024"},"content":{"rendered":"
\n

F\u00f6rsta kvartalet 2024 (1 Jan – 31 Mar)<\/strong>
\u2022 Nettooms\u00e4ttningen uppgick till 186,0 MSEK (140,6), motsvarande en tillv\u00e4xt om 32 procent i SEK och samma tillv\u00e4xt, 32 procent, rensat f\u00f6r valutaeffekter.
\u2022 Samtliga aff\u00e4rsomr\u00e5den visade p\u00e5 underliggande f\u00f6rs\u00e4ljningstillv\u00e4xt rensat f\u00f6r valutaeffekter; Thorax f\u00f6rbrukningsvaror 39 procent, Abdominal f\u00f6rbrukningsvaror 46 procent och Services 11 procent.
\u2022 Bruttomarginal f\u00f6rbrukningsvaror uppgick till 79 procent (81). Total bruttomarginal uppgick till 73 procent (75).
\u2022 R\u00f6relseresultatet (EBIT) \u00f6kade till 19,0 MSEK (11,2). Justerad EBIT \u00f6kade till 19,9 MSEK (12,5).
\u2022 R\u00f6relseresultat f\u00f6re avskrivningar (EBITDA) \u00f6kade till 36,0 MSEK (23,6) motsvarande en EBITDA-marginal om 19 procent (17). Justerat r\u00f6relseresultat f\u00f6re avskrivningar (EBITDA) \u00f6kade till 36,9 MSEK (24,9), motsvarande en justerad EBITDA-marginal om 20 procent (18).
\u2022 Nettoresultatet uppgick till 22,8 MSEK (14,2).
\u2022 Resultat per aktie uppgick till 0,72 SEK (0,48).
\u2022 Kassafl\u00f6de fr\u00e5n den l\u00f6pande verksamheten uppgick till 1,6 MSEK (-12,4), positivt p\u00e5verkat av st\u00e4rkt EBITDA men belastat av \u00f6kad r\u00f6relsekapitalbindning h\u00e4nf\u00f6rlig till \u00f6kad f\u00f6rs\u00e4ljning. Totalt kassafl\u00f6de uppgick till -43,3 MSEK (-48,4), p\u00e5verkat framf\u00f6rallt av investeringar i FoU-projekt om -24,3 MSEK.<\/p>\n

V\u00e4sentliga h\u00e4ndelser under kvartalet<\/strong>
\u2022 Den f\u00f6rsta transplantationen n\u00e5gonsin med ett donatorhj\u00e4rta transporterat \u00f6ver Atlanten har \u00e4gt rum \u2013 m\u00f6jliggjord genom anv\u00e4ndning av XVIVOs hj\u00e4rtteknologi
\u2022 Studie av l\u00e5ngtidsperfusion av levrar med Liver Assist visar att bevaring av lever kan ske upp mot 20 timmar<\/p>\n

V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong>
\u2022 Resultat presenterade fr\u00e5n XVIVOs europeiska kliniska studie f\u00f6r hj\u00e4rtpreservation NIHP 2019 p\u00e5 ISHLT i Prag<\/p>\n

VD-kommentar<\/strong>
\u201c\u00c5ret har b\u00f6rjat med betydande framg\u00e5ngar inom hj\u00e4rtpreservation. Detta st\u00e4rker \u00f6vertygelsen om att v\u00e5r hj\u00e4rtteknologi, XVIVO Heart Assist Transport, kommer spela en avg\u00f6rande roll inom global hj\u00e4rttransplantation. F\u00f6rsta kvartalet startade ocks\u00e5 starkt finansiellt: Nettooms\u00e4ttningen uppgick till 186 MSEK och tillv\u00e4xten i lokala valutor var 32 procent. Utvecklingen drevs av \u00f6kad transplantationsaktivitet samt ett starkt momentum f\u00f6r v\u00e5r lung- och leveraff\u00e4r. Ett fortsatt knivskarpt fokus p\u00e5 kommersiellt genomf\u00f6rande och framsteg i v\u00e5ra utvecklingsprojekt kommer att leda till att fler patienters liv kan r\u00e4ddas och att vi en dag uppn\u00e5r v\u00e5r vision att ingen ska d\u00f6 i v\u00e4ntan p\u00e5 ett nytt organ.\u201d – Christoffer Rosenblad, vd<\/p>\n<\/div>\n

\n

F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n

\n

Christoffer Rosenblad, VD, +46 73 519 21 59, e-post: christoffer.rosenblad@xvivogroup.com
Kristoffer\u00a0Nordstr\u00f6m,\u00a0CFO, +46 73 519 21 64, e-post:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n

\n

Telefonkonferens<\/strong><\/p>\n

\n

Christoffer Rosenblad, VD och Kristoffer Nordstr\u00f6m, CFO, presenterar rapporten vid en telefonkonferens idag klockan 14:00. F\u00f6r anm\u00e4lan till telefonkonferensen, se tidigare pressmeddelande: https:\/\/www.xvivogroup.com\/us\/pressreleases\/telefonkonferens-avseende-delarsrapport-31\/<\/p>\n<\/div>\n

\n

Om oss<\/strong><\/p>\n

\n

XVIVO grundades 1998 och \u00e4r ett medicintekniskt f\u00f6retag dedikerat till att f\u00f6rl\u00e4nga livet f\u00f6r donerade organ s\u00e5 att transplantationsteam runt om i v\u00e4rlden kan r\u00e4dda fler liv. V\u00e5ra l\u00f6sningar g\u00f6r det m\u00f6jligt f\u00f6r ledande kliniker och forskare att t\u00e4nja p\u00e5 gr\u00e4nserna f\u00f6r transplantationsmedicin.\u00a0XVIVO har sitt huvudkontor i G\u00f6teborg och har kontor och forskningsanl\u00e4ggningar p\u00e5 tv\u00e5 kontinenter. Bolaget \u00e4r noterat p\u00e5 Nasdaq Stockholm\u00a0och handlas under symbolen XVIVO. Mer information finns att l\u00e4sa p\u00e5 hemsidan www.xvivogroup.com\/us<\/p>\n<\/div>\n

\n

Denna information \u00e4r s\u00e5dan information som XVIVO Perfusion AB \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2024-04-24 07:30 CEST.<\/em><\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

XVIVO Del\u00e5rsrapport Q1 2024<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

F\u00f6rsta kvartalet 2024 (1 Jan – 31 Mar)\u2022 Nettooms\u00e4ttningen uppgick till 186,0 MSEK (140,6), motsvarande en tillv\u00e4xt om 32 procent…<\/p>\n","protected":false},"template":"","class_list":["post-6737","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q1"],"acf":[],"yoast_head":"\nDel\u00e5rsrapport januari-mars 2024 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del\u00e5rsrapport januari-mars 2024 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"F\u00f6rsta kvartalet 2024 (1 Jan – 31 Mar)\u2022 Nettooms\u00e4ttningen uppgick till 186,0 MSEK (140,6), motsvarande en tillv\u00e4xt om 32 procent...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2024\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2024\\\/\",\"name\":\"Del\u00e5rsrapport januari-mars 2024 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2024-04-24T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2024\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Del\u00e5rsrapport januari-mars 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Del\u00e5rsrapport januari-mars 2024 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/","og_locale":"en_US","og_type":"article","og_title":"Del\u00e5rsrapport januari-mars 2024 - XVIVO","og_description":"F\u00f6rsta kvartalet 2024 (1 Jan – 31 Mar)\u2022 Nettooms\u00e4ttningen uppgick till 186,0 MSEK (140,6), motsvarande en tillv\u00e4xt om 32 procent...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/","name":"Del\u00e5rsrapport januari-mars 2024 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2024-04-24T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Del\u00e5rsrapport januari-mars 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/6737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=6737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}